Top

Published in:

Open Access 01-12-2012 | Research

In vitro evaluation of photon and carbon ion radiotherapy in combination with chemotherapy in glioblastoma cells

Authors: Stephanie E Combs, Lisa Zipp, Stefan Rieken, Daniel Habermehl, Stefan Brons, Marcus Winter, Thomas Haberer, Jürgen Debus, Klaus-Josef Weber

Published in: Radiation Oncology | Issue 1/2012

Abstract

Background

To evaluate the cytotoxic effect of carbon ion radiotherapy and chemotherapy in glioblastoma cells in vitro.

Methods and Materials

The human glioblastoma (GBM) cell line U87 was irradiated with photon radiotherapy (RT) doses of 2 Gy, 4 Gy and 6 Gy. Likewise, irradiation with carbon ions was performed with single carbon doses of 0.125, 0.5, 2 and 3 Gy. Four chemotherapeutic substances, camptothecin, gemcitabine, paclitaxel and cisplatinum, were used for single and combination experiments. The assessment of the effect of single and double treatment on cell viability was performed using the clonogenic growth assay representing the radiobiological gold standard.

Results

The RBE of carbon ions ranges between 3.3 and 3.9 depending on survival level and dose. All chemotherapeutic substances showed a clear does-response relationhips. in their characteristic concentrations. For subsequent combination experiments, two dose levels leading to low and medium reduction of cell survival were chosen. Combination experiments showed additive effects independently of the drugs' mechanisms of action. Paclitaxel and campthothecin demonstrated the most prominent cytotoxic effect in combination with carbon ion radiotherapy.

Conclusion

In conclusion, combination of carbon ion radiotherapy with chemotherapies of different mechanisms of action demonstrates additive effects. The most dominant effect was produced by paclitaxel, followed by camptothecin, as espected from previously published work. The present data serve as an important radiobiological basis for further combination experiments, as well as clinical studies on combination treatments.

Available only for authorised users

Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO, European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups, National Cancer Institute of Canada Clinical Trials Group: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10: 459-66. 10.1016/S1470-2045(09)70025-7CrossRefPubMed

Kramer M, Weyrather WK, Scholz M: The increased biological effectiveness of heavy charged particles: from radiobiology to treatment planning. Technol Cancer Res Treat 2003, 2: 427-36.CrossRefPubMed

Scholz M, Kraft G: Track structure and the calculation of biological effects of heavy charged particles. Adv Space Res 1996, 18: 5-14.CrossRefPubMed

Friedrich T, Scholz U, Elsasser T, Durante M, Scholz M: Calculation of the biological effects of ion beams based on the microscopic spatial damage distribution pattern. Int J Radiat Biol 2011.

Heilmann J, Taucher-Scholz G, Haberer T, Scholz M, Kraft G: Measurement of intracellular dna double-strand break induction and rejoining along the track of carbon and neon particle beams in water. Int J Radiat Oncol Biol Phys 1996, 34: 599-608. 10.1016/0360-3016(95)02112-4CrossRefPubMed

Murakami M, Eguchi-Kasai K, Sato K, Minohara S, Yatagai F, Kanai T: Differences in heavy-ion-induced DNA double-strand breaks in a mouse DNA repair-deficient mutant cell line (SL3-147) before and after chromatin proteolysis. J Radiat Res (Tokyo) 1995, 36: 258-64. 10.1269/jrr.36.258CrossRef

Combs SE, Bohl J, Elsasser T, Weber KJ, Schulz-Ertner D, Debus J, Weyrather WK: Radiobiological evaluation and correlation with the local effect model (LEM) of carbon ion radiation therapy and temozolomide in glioblastoma cell lines. Int J Radiat Biol 2009, 85: 126-37. 10.1080/09553000802641151CrossRefPubMed

Tsuboi K, Moritake T, Tsuchida Y, Tokuuye K, Matsumura A, Ando K: Cell cycle checkpoint and apoptosis induction in glioblastoma cells and fibroblasts irradiated with carbon beam. J Radiat Res (Tokyo) 2007, 48: 317-25. 10.1269/jrr.06081CrossRef

Tsuboi K, Tsuchida Y, Nose T, Ando K: Cytotoxic effect of accelerated carbon beams on glioblastoma cell lines with p53 mutation: clonogenic survival and cell-cycle analysis. Int J Radiat Biol 1998, 74: 71-9. 10.1080/095530098141744CrossRefPubMed

10.

Kitabayashi H, Shimada H, Yamada S, Yasuda S, Kamata T, Ando K, Tsujii H, Ochiai T: Synergistic growth suppression induced in esophageal squamous cell carcinoma cells by combined treatment with docetaxel and heavy carbon-ion beam irradiation. Oncol Rep 2006, 15: 913-8.PubMed

11.

Abdollahi A, Lipson KE, Sckell A, Zieher H, Klenke F, Poerschke D, Roth A, Han X, Krix M, Bischof M, Hahnfeldt P, Grone HJ, Debus J, Hlatky L, Huber PE: Combined therapy with direct and indirect angiogenesis inhibition results in enhanced antiangiogenic and antitumor effects. Cancer Res 2003, 63: 8890-8.PubMed

12.

Abdollahi A, Lipson KE, Han X, Krempien R, Trinh T, Weber KJ, Hahnfeldt P, Hlatky L, Debus J, Howlett AR, Huber PE: SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res 2003, 63: 3755-63.PubMed

13.

Bischof M, Abdollahi A, Gong P, Stoffregen C, Lipson KE, Debus JU, Weber KJ, Huber PE: Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells. Int J Radiat Oncol Biol Phys 2004, 60: 1220-32. 10.1016/j.ijrobp.2004.07.689CrossRefPubMed

14.

Mizoe JE, Tsujii H, Hasegawa A, Yanagi T, Takagi R, Kamada T, Tsuji H, Takakura K, Organizing Committee of the Central Nervous System Tumor Working Group: Phase I/II clinical trial of carbon ion radiotherapy for malignant gliomas: combined X-ray radiotherapy, chemotherapy, and carbon ion radiotherapy. Int J Radiat Oncol Biol Phys 2007, 69: 390-6. 10.1016/j.ijrobp.2007.03.003CrossRefPubMed

15.

Combs SE, Kieser M, Rieken S, Habermehl D, Jäkel O, Haberer T, Nikoghosyan A, Haselmann R, Unterberg A, Wick W, Debus J: Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial. BMC Cancer 2010, 10: 478. 10.1186/1471-2407-10-478PubMedCentralCrossRefPubMed

16.

Kano M, Yamada S, Hoshino I, Murakami K, Akutsu Y, Sakata H, Nishimori T, Usui A, Miyazawa Y, Kamada T, Tsujii H, Matsubara H: Effects of carbon-ion radiotherapy combined with a novel histone deacetylase inhibitor, cyclic hydroxamic-acid-containing peptide 31 in human esophageal squamous cell carcinoma. Anticancer Res 2009, 29: 4433-8.PubMed

17.

Oertel S, Thiemann M, Richter K, Weber KJ, Huber PE, Perez RL, Brons S, Bischof M, Kulozik AE, Ehemann V, Debus J, Blattmann C: Combination of suberoylanilide hydroxamic acid with heavy ion therapy shows promising effects in infantile sarcoma cell lines. Radiat Oncol 2011, 6: 119. 10.1186/1748-717X-6-119PubMedCentralCrossRefPubMed

18.

Elsasser T, Kramer M, Scholz M: Accuracy of the local effect model for the prediction of biologic effects of carbon ion beams in vitro and in vivo. Int J Radiat Oncol Biol Phys 2008, 71: 866-72. 10.1016/j.ijrobp.2008.02.037CrossRefPubMed

19.

Elsasser T, Scholz M: Improvement of the local effect model (LEM)--implications of clustered DNA damage. Radiat Prot Dosimetry 2006, 122: 475-7.CrossRefPubMed

20.

Jones B, Sanghera P: Estimation of radiobiologic parameters and equivalent radiation dose of cytotoxic chemotherapy in malignant glioma. Int J Radiat Oncol Biol Phys 2007, 68: 441-8. 10.1016/j.ijrobp.2006.12.025CrossRefPubMed

Title: In vitro evaluation of photon and carbon ion radiotherapy in combination with chemotherapy in glioblastoma cells
Authors: Stephanie E Combs
Lisa Zipp
Stefan Rieken
Daniel Habermehl
Stefan Brons
Marcus Winter
Thomas Haberer
Jürgen Debus
Klaus-Josef Weber
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: Radiation Oncology / Issue 1/2012
Electronic ISSN: 1748-717X
DOI: https://doi.org/10.1186/1748-717X-7-9

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

In vitro evaluation of photon and carbon ion radiotherapy in combination with chemotherapy in glioblastoma cells

Abstract

Background

Methods and Materials

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods and Materials

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2012

ACR Appropriateness Criteria® Resectable Rectal Cancer

Intraoperative radiation therapy with the photon radiosurgery system in locally advanced and recurrent rectal cancer: retrospective review of the Cleveland clinic experience

Analysis of inter-fraction setup errors and organ motion by daily kilovoltage cone beam computed tomography in intensity modulated radiotherapy of prostate cancer

Autophagy inhibition plays the synergetic killing roles with radiation in the multi-drug resistant SKVCR ovarian cancer cells

Factors influencing heterogeneity of radiation-induced DNA-damage measured by the alkaline comet assay

Treatment and prognosis of patients with late rectal bleeding after intensity-modulated radiation therapy for prostate cancer